Merkel Cell Carcinoma Treatment in Finland in 1986-2016-A Real-World Data Study

Show full item record



Permalink

http://hdl.handle.net/10138/317683

Citation

Sahi , H , Their , J , Gissler , M & Koljonen , V 2020 , ' Merkel Cell Carcinoma Treatment in Finland in 1986-2016-A Real-World Data Study ' , Cancers , vol. 12 , no. 5 . https://doi.org/10.3390/cancers12051224

Title: Merkel Cell Carcinoma Treatment in Finland in 1986-2016-A Real-World Data Study
Author: Sahi, Helka; Their, Jenny; Gissler, Mika; Koljonen, Virve
Contributor: University of Helsinki, HUS Inflammation Center
University of Helsinki, Plastiikkakirurgian yksikkö
University of Helsinki, HUS Musculoskeletal and Plastic Surgery
Date: 2020-05
Language: eng
Number of pages: 16
Belongs to series: Cancers
ISSN: 2072-6694
URI: http://hdl.handle.net/10138/317683
Abstract: Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In this study, we reviewed the real-world data on different treatments given to MCC patients in Finland in 1986-2016. We used the Finnish Cancer Registry database to find MCC patients and the Hospital Discharge Register and the Cause-of-Death Register to obtain treatment data. We identified 376 MCC patients and 33 different treatment entities and/or combinations of treatment. An increase was noted in the incidence of MCC since 2005. Therefore, the cohort was divided into two groups: the "early" group with time of diagnosis between years 1986 and 2004 and the "late" group with time of diagnosis between 2005 and 2016. The multitude of different treatment combinations is a relatively new phenomenon; before the year 2005, only 11 treatments or treatment combinations were used for MCC patients. Our data show that combining radiation therapy with simple excision provided a survival advantage, which was, however, lost after adjustment for stage or age. Our registry study serves as a baseline treatment efficacy comparison as we move into the age of immunotherapy in MCC. Standardizing the treatment of MCC patients in Finland requires more work on awareness and multidisciplinary co-operation.
Subject: Merkel cell carcinoma
treatment
radiation therapy
immunotherapy
surgical intervention
survival
multidisciplinary communication
RADIATION-THERAPY
RARE CANCER
EPIDEMIOLOGY
POLYOMAVIRUS
RADIOTHERAPY
DIAGNOSIS
SURVIVAL
OUTCOMES
CHEMOTHERAPY
IRRADIATION
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
cancers_12_01224_v2.pdf 796.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record